Clinical Impact of New Data From CROI 2017
Source: 2017 Conference on Retroviruses and Opportunistic Infections*

Slideset

Clinical Impact of New Data From CROI 2017

Expert faculty members Joel E. Gallant, MD, MPH, and Charles B. Hicks, MD, summarize key studies from this important annual conference.
Format: Microsoft PowerPoint (.ppt)
File size: 1.38 MB
Date posted: 3/3/2017
  • Selecting ART for an Aging Patient With Multiple Comorbidities and Potential Drug–Drug Interactions

    David A. Wohl MD - 5/31/2017    
    In an older patient managing hypertension, reactive airways disease, and moderate renal insufficiency, what ART regimen would you recommend?
  • Weighing Boosted vs Unboosted Options for a Patient Who Requires Treatment Prior to Availability of Resistance Data

    Eric S. Daar MD - 6/21/2017    
    For a newly-diagnosed patient with an OI and pending resistance test results, when and with what would you recommend initiating ART?
  • Optimizing ART for a Patient With PI Intolerance and a History of Resistance and Nonadherence

    Eric S. Daar MD - 6/21/2017    1 comment / Last Comment: 6/22/2017
    Would you switch a virologically suppressed patient who is experiencing PI toxicity to a PI-sparing regimen if they had history of nonadherence and resistance?
  • Weighing Boosted vs Unboosted Options for a Patient With Comorbidities Who Desires an STR

    Eric S. Daar MD - 6/21/2017    
    What is the optimal ART regimen for a patient with CKD and CVD who desires an STR?
  • Choosing Statins for Patients With Dyslipidemia and Elevated CVD Risk

    David A. Wohl MD - 6/1/2017    1 comment / Last Comment: 6/16/2017
    Which statins should be avoided in patients receiving boosted ART regimens?